Chamath Palihapitiya

The coverage is coming out of this phase three clinical trial data release that Lily put out last month.

So everyone's going...

crazy over the data, which continues to show pretty amazing results.

So unlike Terzepatide, which is kind of Lilly's main

product today, which is a dual agonist.

It's got two peptides in it that bind to different receptors, the GLP-1, the GIP receptor.

This other one now also binds to glucagon, which is a third receptor.

And that glucagon receptor binding peptide causes the cells to increase their metabolism, which actually accelerates fat energy consumption

over what would typically be muscle energy consumption, it's more likely to burn up fat early on, which causes more quick fat loss, but also reduces muscle loss.

And some of the other data that's now coming out shows non HDL cholesterol down 27% triglycerides down 41% liver fat down 80% to 80% reduction of liver fat, a one C drops

from 7.9% to 6% in 40 weeks, which is amazing, by the way, if you're diabetic and your A1C drops that much in a couple of months, it's literally a life-saving product.

The average user in this phase three trial saw their weight decline from 214 pounds.

They lost 37 pounds.

That's compared to six pounds on placebo.

in 40 weeks.

And modest side effects, 20% people felt more nauseous than the people that were on the placebo.

There's a lot of other

Separate studies that are being done now that are showing significant reductions in inflammatory signaling molecules.

So systemic signaling of like, hey, cells are in distress, triggers this kind of inflammatory process that can have a lot of other damage to your body, can accelerate aging.

And so one of the other conversations is that reticrutide might actually be kind of a de-aging drug as well.